No Data
No Data
Pharmaron has repurchased approximately 6.91616 million shares of A shares as of the end of June.
Pharmaron (03759) announced that as of June 30, 2024, the company used its own funds to repurchase shares through a share repurchase special securities account in a centralized bidding trading manner. The number of repurchased shares was approximately 6.91616 million shares, accounting for 0.39% of the company's current total share capital. The highest transaction price for repurchased shares was 22.27 yuan/share, the lowest transaction price was 18.44 yuan/share, and the total transaction amount was approximately 151 million yuan (excluding transaction fees). In addition, the company recently received a notice from Ningbo Long Thai Kang Investment Management Co., Ltd., the actual controller of the company's concerted action.
Pharmaron (03759.HK) spent 19.265 million yuan to repurchase 1.042 million A-shares on July 2nd.
On July 2, Gelonhui announced that Pharmaron (03759.HK) will spend 19.265 million yuan to buy back 1.042 million A shares on July 2, 2024, with a repurchase price of 18.38-18.6 yuan per share.
Pharmaron (03759) spent RMB 1.434 million on June 27th to repurchase 77,500 A-shares.
Pharmaron (03759) announced that on June 27, 2024, the company spent RMB 1.434 million to repurchase 77,500 A-shares at a repurchase price of RMB 18.44-18.76 per share.
Hong Kong stocks fluctuate | CRO concept stocks collectively decline, the industry still faces short-term pressure, and industry clearance is expected to improve the market share of leading companies.
CRO concept stocks collectively fell. As of the time of publication, Pharmaron (03759) fell 3.22%, reporting 8.73 Hong Kong dollars; Wuxi Apptec (02359) fell 3.04%, reporting 30.25 Hong Kong dollars; Tigermed (03347) fell 2.84%, reporting 29.05 Hong Kong dollars.
Pharmaron's Earnings Likely Weighed by Biotech Sector Disruptions -- Market Talk
0656 GMT - Pharmaron's earnings will likely be under pressure in the coming months given the disruptions witnessed by the biotech sector due to continuing U.S.-China tensions, Deutsche Bank analyst Cy
Pharmaron (03759) has received approximately $86.821 million as the down payment for selling equity investment in Proteologix.
Pharmaron (03759) announced the sale of the group's equity investment in Proteologix.
No Data